{"id":"reteplase-10-10-u","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Bleeding (major and minor)"},{"rate":"0.7–1","effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":"<1","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Reteplase is a recombinant plasminogen activator that works by binding to fibrin in thrombi and catalyzing the conversion of plasminogen to plasmin. Plasmin then degrades the fibrin matrix of the clot, leading to thrombolysis. The 10+10 U dosing regimen refers to a double-bolus administration protocol (10 units followed by a second 10-unit bolus 30 minutes later) used to optimize clot dissolution.","oneSentence":"Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:16.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction (AMI) for thrombolysis"},{"name":"Acute ischemic stroke"}]},"trialDetails":[{"nctId":"NCT00178620","phase":"PHASE4","title":"Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2003-09","conditions":"Heart Disease, Myocardial Infarction, Acute Myocardial Infarction","enrollment":390},{"nctId":"NCT00806403","phase":"PHASE4","title":"Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2001-11","conditions":"Acute Myocardial Infarction","enrollment":205}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapilysin"],"phase":"marketed","status":"active","brandName":"reteplase 10+10 U","genericName":"reteplase 10+10 U","companyName":"Sahlgrenska University Hospital","companyId":"sahlgrenska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin. Used for Acute myocardial infarction (AMI) for thrombolysis, Acute ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}